Genmab — December 2019
-
“In many ways, the Alcyone data are a watershed moment,” Mark Wildgust, Janssen’s VP of global medical affairs for oncology, said. “We’ve now demonstrated that when using daratumumab, we see a survival benefit. That’s been something that I think the medical community’s been waiting for.” https://www.fiercepharma.com/pharma/ash-j-j-s-darzalex-cuts-death-risk-by-40-new-myeloma-patients
-
-
-
-
-
-
-
-
Jan er i topform på Q&A.
-
Genmab vil forsætte med at levere unikke resultater fra pipelinen med "knock the socks" data.
-
Konklusion omkring Dara er, at midlet gør alle kombinationer bedre.
-
https://assets.main.pro2.maf.wdc.west.com/58d363a9eade4590ad02d99ada6dabbe/191209_Genmab_RD_Update_ASH_Data_Review.pdf Det ser ud til, at CD3xCD20 virkelig begynder, at vise resultater i DLBCL ved 12 mg
-
CD3/CD20 safety helt i top
-
Stor begejstring for CANDOR (KRd + dara) resultater hos eksperterne på Twitter
-
God morgen.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind